117 集

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

Project Oncology‪®‬ ReachMD

    • 科學

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

    Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

    Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

    Guest: Alan Bryce, MD



    Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.

    mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib

    mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib

    Host: Charles Turck, PharmD, BCPS, BCCCP

    Guest: Neeraj Agarwal, MD, FASCO



    TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a 37 percent reduction in risk of progression or death among those who received enzalutamide plus talazoparib. Dive further into the findings and their implications for patients with mCRPC with Dr. Charles Turck and Dr. Neeraj Agarwal, Professor of Medicine at the Huntsman Cancer Institute at the University of Utah.

    Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access

    Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access

    Host: Rishi Sekar, MD



    A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in the area. Dive further into the results with Dr. Rishi Sekar, who presented the “Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations” session at the 2024 ASCO Genitourinary Cancers Symposium.

    Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

    Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

    Host: Jacob Sands, MD

    Guest: Aakesh Desai, MD, MPH



    According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr. Aakash Desai, an Assistant Professor of Medicine at the O’Neal Cancer Center at the University of Alabama at Birmingham.

    Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification

    Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification

    Host: Zachery Reichert MD, PhD



    If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with Dr. Zachery Reichert, who presented the “Sequencing Hormonal Therapies After Treatment Intensification” session at the 2024 ASCO Genitourinary Cancers Symposium.

    Emerging Strategies in Multi-Cancer Early Detection

    Emerging Strategies in Multi-Cancer Early Detection

    Host: Charles Turck, PharmD, BCPS, BCCCP

    Guest: Tomasz Beer, MD, FACP

    Guest: Betsy O'Donnell, MD



    Recent estimates show that only 14 percent of cancers are detected through routine screening, meaning the majority of patients are diagnosed after the onset of clinical symptoms. But multi-cancer early detection (MCED) tests offer the opportunity to potentially expand our ability to detect cancer through a single blood draw. Explore how MCED tests might help bridge the gaps that exist in today’s cancer screening paradigm and the recent studies on these tests with Drs. Tom Beer and Betsy O’Donnell. Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation, and Dr. O’Donnell is the Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.

關於科學的熱門 Podcast

老高與小茉 Mr & Mrs Gao
老高與小茉 Mr & Mrs Gao
Hidden Brain
Hidden Brain, Shankar Vedantam
Discovery
BBC World Service
Kurzgesagt - In a Nutshell
Kurzgesagt
Science, Quickly
Scientific American
Science Vs
Spotify Studios

你可能也會喜歡